AbbVie to Acquire Immunology Drugmaker Apogee Therapeutics for $10.9 Billion

Biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.

The deal strengthens its immunology portfolio and accelerates AbbVie’s expansion into respiratory diseases through a pipeline of clinical-stage therapies targeting atopic dermatitis and asthma.

AbbVie will pay $135.11 per share in cash for all outstanding Apogee shares.

Read more at BENZINGA